LU90341I2 - 75 Ug desogestrel in the absence of ethinyl estradiol (cerazette) - Google Patents
75 Ug desogestrel in the absence of ethinyl estradiol (cerazette)Info
- Publication number
- LU90341I2 LU90341I2 LU90341C LU90341C LU90341I2 LU 90341 I2 LU90341 I2 LU 90341I2 LU 90341 C LU90341 C LU 90341C LU 90341 C LU90341 C LU 90341C LU 90341 I2 LU90341 I2 LU 90341I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- desogestrel
- cerazette
- absence
- ketodesogestrel
- regimen
- Prior art date
Links
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 title abstract 4
- 229960004976 desogestrel Drugs 0.000 title abstract 4
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 title 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 title 1
- 229960002568 ethinylestradiol Drugs 0.000 title 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 abstract 2
- 229940127234 oral contraceptive Drugs 0.000 abstract 2
- 239000003539 oral contraceptive agent Substances 0.000 abstract 2
- 206010027514 Metrorrhagia Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 231100000546 inhibition of ovulation Toxicity 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000025661 ovarian cyst Diseases 0.000 abstract 1
- 230000027758 ovulation cycle Effects 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Disclosed is an oral contraceptive regimen containing daily dosage units each containing from 70 to 80 micrograms of desogestrel, 3-ketodesogestrel or mixtures thereof. It has been found that by making a selection of desogestrel or 3-ketodesogestrel at the described dosages in an oral contraceptive regimen administered over the entire menstrual cycle (e.g. 28 days), effective ovulation inhibition is achieved and intermenstrual bleeding is avoided, while acceptable cycle control is retained. Moreover, the regimen also prevents the formation of persistent ovarian cysts.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP90203371 | 1990-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU90341I2 true LU90341I2 (en) | 1999-03-29 |
Family
ID=8205203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU90341C LU90341I2 (en) | 1990-12-17 | 1999-01-27 | 75 Ug desogestrel in the absence of ethinyl estradiol (cerazette) |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5461041A (en) |
| EP (1) | EP0491443B1 (en) |
| JP (1) | JPH04290829A (en) |
| KR (1) | KR100221008B1 (en) |
| CN (1) | CN1036834C (en) |
| AT (1) | ATE135218T1 (en) |
| AU (1) | AU649082B2 (en) |
| CA (1) | CA2057714C (en) |
| DE (2) | DE19975011I2 (en) |
| DK (1) | DK0491443T3 (en) |
| ES (1) | ES2087237T3 (en) |
| FI (1) | FI98984C (en) |
| GR (1) | GR3020180T3 (en) |
| IE (1) | IE71202B1 (en) |
| LU (1) | LU90341I2 (en) |
| NL (1) | NL990003I2 (en) |
| NO (2) | NO2002013I2 (en) |
| NZ (1) | NZ240969A (en) |
| PT (1) | PT99818B (en) |
| ZA (1) | ZA919732B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4133680A1 (en) * | 1991-10-11 | 1993-04-15 | Metallgesellschaft Ag | STABILIZED STRENGTH, USE OF THE STABILIZED STRENGTH AND METHOD FOR THEIR PRODUCTION |
| DE4227989A1 (en) * | 1992-08-21 | 1994-06-09 | Schering Ag | Agent for transdermal application containing 3-keto-desogestrel |
| US5395627A (en) * | 1992-09-04 | 1995-03-07 | Akzo N.V. | Pharmaceutical granulate |
| US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
| ZA949929B (en) * | 1993-12-23 | 1995-08-23 | Akzo Nobel Nv | Sugar-coated pharmaceutical dosage unit. |
| DE4405590C1 (en) * | 1994-02-22 | 1995-07-20 | Hesch Rolf Dieter Prof Dr Med | Postmenopausal hormone treatment |
| CA2200754C (en) * | 1994-09-22 | 2008-04-15 | Pieter De Haan | Process of making dosage units by wet granulation |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
| US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| AU4134599A (en) * | 1998-04-07 | 1999-10-25 | Akzo Nobel N.V. | Progestogen-only contraceptive kit |
| WO2000009136A1 (en) * | 1998-08-11 | 2000-02-24 | Akzo Nobel N.V. | Progestogen-only contraceptive kit providing good cycle control |
| US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| GB0114746D0 (en) * | 2001-06-16 | 2001-08-08 | Boots Co Plc | Medicinal composition |
| US6574033B1 (en) | 2002-02-27 | 2003-06-03 | Iridigm Display Corporation | Microelectromechanical systems device and method for fabricating same |
| TW200403075A (en) * | 2002-05-29 | 2004-03-01 | Akzo Nobel Nv | Progestagenic dosage units |
| AU2004234057A1 (en) * | 2003-04-29 | 2004-11-11 | Akzo Nobel N.V. | Antisolvent solidification process |
| DE102005053771A1 (en) * | 2005-11-09 | 2007-05-10 | Grünenthal GmbH | Dosage form for hormonal contraception |
| DE202010010589U1 (en) | 2010-07-22 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | Estrogen-free formulation for oral contraception, preferably usable for women with conscious / unconscious lactose intolerance or with deliberate lactose-free contraception |
| EP2730284A1 (en) * | 2012-11-12 | 2014-05-14 | Naari AG | Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation |
| WO2017000081A1 (en) * | 2015-06-30 | 2017-01-05 | 上海交通大学 | Applications of etonogestrel in preparation of products for resisting against prostate cancer |
| US11679114B2 (en) | 2021-07-26 | 2023-06-20 | Navad Life Sciences Pte | Progestogen-only oral contraception |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4066757A (en) * | 1973-03-26 | 1978-01-03 | Ortho Pharmaceutical Corporation | Oral contraceptive regimen |
| ES2054784T3 (en) * | 1987-08-08 | 1994-08-16 | Akzo Nv | A METHOD FOR THE MANUFACTURE OF AN IMPLANT. |
-
1991
- 1991-12-09 IE IE427191A patent/IE71202B1/en not_active IP Right Cessation
- 1991-12-10 ZA ZA919732A patent/ZA919732B/en unknown
- 1991-12-12 DE DE1999175011 patent/DE19975011I2/en active Active
- 1991-12-12 ES ES91203328T patent/ES2087237T3/en not_active Expired - Lifetime
- 1991-12-12 DE DE69117902T patent/DE69117902T2/en not_active Expired - Lifetime
- 1991-12-12 AT AT91203328T patent/ATE135218T1/en not_active IP Right Cessation
- 1991-12-12 EP EP91203328A patent/EP0491443B1/en not_active Expired - Lifetime
- 1991-12-12 DK DK91203328.9T patent/DK0491443T3/en active
- 1991-12-13 NZ NZ240969A patent/NZ240969A/en not_active IP Right Cessation
- 1991-12-13 AU AU89678/91A patent/AU649082B2/en not_active Expired
- 1991-12-16 PT PT99818A patent/PT99818B/en not_active IP Right Cessation
- 1991-12-16 KR KR1019910023066A patent/KR100221008B1/en not_active Expired - Lifetime
- 1991-12-16 NO NO2002013C patent/NO2002013I2/en unknown
- 1991-12-16 CA CA002057714A patent/CA2057714C/en not_active Expired - Lifetime
- 1991-12-16 FI FI915913A patent/FI98984C/en active
- 1991-12-16 NO NO914970A patent/NO178686C/en not_active IP Right Cessation
- 1991-12-17 CN CN91107997A patent/CN1036834C/en not_active Expired - Lifetime
- 1991-12-17 JP JP3333717A patent/JPH04290829A/en active Pending
-
1994
- 1994-01-19 US US08/183,644 patent/US5461041A/en not_active Expired - Lifetime
-
1996
- 1996-06-07 GR GR960401542T patent/GR3020180T3/en unknown
-
1999
- 1999-01-22 NL NL990003C patent/NL990003I2/en unknown
- 1999-01-27 LU LU90341C patent/LU90341I2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU90341I2 (en) | 75 Ug desogestrel in the absence of ethinyl estradiol (cerazette) | |
| GB8716431D0 (en) | Combination dosage form | |
| NZ234051A (en) | Treating post-menopausal disorders using an estrogenic compound mixed with a compound having progestational activity | |
| KR960704553A (en) | PREPARATION FOR SUBSTITUTION THERAPY CONTAINING AT LEAST ONE PROGESTOGEN AND AT LEAST ONE ESTROGEN | |
| IL122109A0 (en) | A two-stage pharmaceutical preparation for hormonal contraception and a kit containing the same | |
| BG104451A (en) | Antiestrogen and progestin-containing peroral contraceptives | |
| MX9804395A (en) | Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen. | |
| NZ333750A (en) | Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen | |
| RU94040720A (en) | Antiprogestin estrogen (progestin), method of oral contraception and menstruation control, pharmaceutical composition and medicinal agents set | |
| Vikhliaeva | Current trends in the development of hormonal contraception | |
| MX9707009A (en) | Once-a-month-injectable useful as depot contraceptive and in hormone replacement therapy for perimenopausal and premenopausal women. |